Story perspectives

WHO Endorses GLP-1 Drugs for Obesity, Sparks Debate

12/31/2025

30 5

Summary

Story summary

In 2025, the World Health Organization (WHO) recommended GLP-1 drugs as a primary treatment for obesity, marking a shift from its previous stance against pharmaceutical solutions.
Critics argue this approach overlooks social and economic factors contributing to obesity, such as poverty and limited access to nutritious food.
GLP-1s can aid weight loss and improve health markers, but they require lifelong dependency and do not replace the need for exercise and a healthy diet.
Public health advocates say reliance on these drugs signals surrender to the food industry and call for systemic changes to promote nutrition and physical activity.

1 of 1

Story summary

In 2025, the World Health Organization (WHO) recommended GLP-1 drugs as a primary treatment for obesity, marking a shift from its previous stance against pharmaceutical solutions.
Critics argue this approach overlooks social and economic factors contributing to obesity, such as poverty and limited access to nutritious food.
GLP-1s can aid weight loss and improve health markers, but they require lifelong dependency and do not replace the need for exercise and a healthy diet.
Public health advocates say reliance on these drugs signals surrender to the food industry and call for systemic changes to promote nutrition and physical activity.